- Home
- ABLV vs SABS Comparison
ABLV vs SABS Comparison
Compare ABLV & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABLV
- SABS
- Stock Information
- Founded
- ABLV 2015
- SABS 2014
- Country
- ABLV China
- SABS United States
- Employees
- ABLV N/A
- SABS N/A
- Industry
- ABLV
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- ABLV
- SABS Health Care
- Exchange
- ABLV Nasdaq
- SABS Nasdaq
- Market Cap
- ABLV 48.6M
- SABS 15.8M
- IPO Year
- ABLV N/A
- SABS N/A
- Fundamental
- Price
- ABLV $0.84
- SABS $2.64
- Analyst Decision
- ABLV
- SABS Strong Buy
- Analyst Count
- ABLV 0
- SABS 5
- Target Price
- ABLV N/A
- SABS $11.80
- AVG Volume (30 Days)
- ABLV 8.4K
- SABS 35.3K
- Earning Date
- ABLV 04-23-2025
- SABS 08-07-2025
- Dividend Yield
- ABLV N/A
- SABS N/A
- EPS Growth
- ABLV N/A
- SABS N/A
- EPS
- ABLV N/A
- SABS N/A
- Revenue
- ABLV $128,932,647.00
- SABS $377,835.00
- Revenue This Year
- ABLV N/A
- SABS N/A
- Revenue Next Year
- ABLV N/A
- SABS N/A
- P/E Ratio
- ABLV N/A
- SABS N/A
- Revenue Growth
- ABLV N/A
- SABS N/A
- 52 Week Low
- ABLV $0.55
- SABS $1.00
- 52 Week High
- ABLV $1.90
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- ABLV 30.67
- SABS 77.22
- Support Level
- ABLV $0.84
- SABS $1.72
- Resistance Level
- ABLV $1.13
- SABS $2.72
- Average True Range (ATR)
- ABLV 0.05
- SABS 0.19
- MACD
- ABLV -0.02
- SABS 0.10
- Stochastic Oscillator
- ABLV 3.45
- SABS 91.89
About ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.